Publications by authors named "Bernard Chao"
Biosimilar drugs enter the United States market well after they enter the European market. That is likely because pharmaceutical companies have many more patents in the United States than in Europe. But why is patent coverage of biological drugs so much more extensive in United States? This case study seeks to answer this question for drug formulation patents.
View Article and Find Full Text PDFBiological patent thickets and delayed access to biosimilars, an American problem.
J Law Biosci
September 2022
Article Synopsis
- The study investigates if patent thickets for biologic drugs are causing delays in bringing biosimilars to market, comparing data across the U.S., Canada, and the UK.
- Findings show that the U.S. has significantly more patents asserted against biosimilars (9-12 times more) compared to Canada and the UK, resulting in slower market entry for biosimilars in the U.S.
- The research highlights that many U.S. patents for Abbvie's Humira are duplicative, making it costly for challengers, and suggests policy changes to reduce these patent thickets.